The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa

被引：41

作者：

Frank, Guido K. W. ^{[1
,2
]}

Shott, Megan E. ^{[1
]}

Hagman, Jennifer O. ^{[1
]}

Schiel, Marissa A. ^{[1
]}

DeGuzman, Marisa C. ^{[1
,2
]}

Rossi, Brogan ^{[1
]}

机构：

[1] Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO 80045 USA

[2] Univ Colorado, Dept Neurosci, Anschutz Med Campus, Aurora, CO 80045 USA

来源：

INTERNATIONAL JOURNAL OF EATING DISORDERS | 2017年 / 50卷 / 04期

关键词：

anorexia nervosa; aripiprazole; dopamine; eating disorder; medication; receptor; treatment; weight gain;

D O I：

10.1002/eat.22704

中图分类号：

B849 [应用心理学];

学科分类号：

040203 ;

摘要：

ObjectiveFinding medication to support treatment of anorexia nervosa has been difficult. Neuroscience-based approaches may help in this effort. Recent brain imaging studies in adults and adolescents with anorexia nervosa suggest that dopamine-related reward circuits are hypersensitive and could provide a treatment target. MethodsHere, we present a retrospective chart review of 106 adolescents with anorexia nervosa some of whom were treated with the dopamine D2 receptor partial agonist aripiprazole during treatment in a specialized eating disorder program. ResultsThe results show that aripiprazole treatment was associated with greater increase in body mass index (BMI) during treatment. DiscussionThe use of dopamine receptor agonists may support treatment success in anorexia nervosa and should be further investigated.

引用

页码：447 / 450

页数：4

共 50 条

[1] Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic
Keck, PE
McElroy, SL
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (04) : 655 - 662
[2] Aripiprazole, a Partial Dopamine Agonist to Improve Adolescent Anorexia Nervosa-A Case Series
Frank, Guido K. W.
INTERNATIONAL JOURNAL OF EATING DISORDERS, 2016, 49 (05) : 529 - 533
[3] Aripiprazole acts as a selective dopamine D2 receptor partial agonist
Wood, Martyn
Reavill, Charlie
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (06) : 771 - 775
[4] Pharmacology of aripiprazole, a novel antipsychotic:: dopamine D2 receptor partial agonist
Kikuchi, T
Arlene, S
Yocca, F
Tadori, Y
Hirose, T
McQuade, R
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (03) : 190 - 190
[5] Aripiprazole, a dopamine D2 receptor partial agonist activates nuclear CaMKII in dopaminergic neurons
Sawai, Masahiro
Shioda, Norifumi
Fukunaga, Kohji
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 143P - 143P
[6] The partial agonist of the dopamine receptor 2, Aripiprazole, facilitates extinction in adolescent rats
Ganella, D. E.
Madsen, H. B.
Zbukvic, I. C.
Coulthard, R. W.
Lee-Kardashyan, L.
Lawrence, A. J.
Kim, J. H.
JOURNAL OF NEUROCHEMISTRY, 2014, 130 : 35 - 35
[7] Aripiprazole, a novel antipsychotic, is a potent partial agonist at human dopamine D2 receptors
Burris, KD
Molski, TF
Ryan, E
Xu, C
Tottori, K
Kikuchi, T
Yocca, FD
Molinoff, PB
SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 88 - 88
[8] Macronutrient intake associated with weight gain in adolescent girls with anorexia nervosa
Baskaran, Charumathi
Carson, Traci L.
Reyes, Karen J. Campoverde
Becker, Kendra R.
Slattery, Meghan J.
Tulsiani, Shreya
Eddy, Kamryn T.
Anderson, Ellen J.
Hubbard, Jane L.
Misra, Madhusmita
Klibanski, Anne
INTERNATIONAL JOURNAL OF EATING DISORDERS, 2017, 50 (09) : 1050 - 1057
[9] Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys
Paul W. Czoty
H. Donald Gage
Pradeep K. Garg
Sudha Garg
Michael A. Nader
Psychopharmacology, 2014, 231 : 613 - 619
[10] Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys
Czoty, Paul W.
Gage, H. Donald
Garg, Pradeep K.
Garg, Sudha
Nader, Michael A.
PSYCHOPHARMACOLOGY, 2014, 231 (03) : 613 - 619

← 1 2 3 4 5 →